Evidence map›Paper›PMID 41983435›Full record

ArticleJournal of diabetes investigation2026

ChREBP drives β-cell proliferation under metabolic stress but not in pregnancy-induced β-cell expansion.

Sodai Kubota, Seiya Banno, Katsumi Iizuka, Hiromi Tsuchida, Saki Kubota-Okamoto, Teruaki Sakurai, Yoshihiro Takahashi, Toshinori Imaizumi, Takehiro Kato, Yukio Horikawa and 11 more

Abstract read
In one paragraph

Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sodai KubotaDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-6072-0080
Seiya BannoDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0009-0000-7345-7974
Katsumi IizukaDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-9837-6238
Hiromi TsuchidaDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0009-0004-1542-3900
Saki Kubota-OkamotoDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0009-0001-4747-6415
Teruaki SakuraiDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0001-5804-7635
Yoshihiro TakahashiDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-4841-9914
Toshinori ImaizumiDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0001-8808-1893
Takehiro KatoDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0003-3236-2463
Yukio HorikawaDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0001-7268-6871
Shin TsunekawaDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-9890-5777
Ryota UsuiYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0000-0002-4641-0158
Hisato TatsuokaYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0000-0002-0669-6825
Shinsuke TokumotoYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0000-0002-4070-6724
Takaaki MurakamiDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0003-3844-1138
Yuuka FujiwaraYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0009-0002-4151-457X
Hitoshi KuwataYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0009-0000-5498-3282
Yuji YamazakiYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0009-0007-5876-8695
Yuichiro YamadaYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0000-0003-1623-0815
Yutaka SeinoYutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Osaka, Japan.ORCID https://orcid.org/0000-0002-1099-7989
Daisuke YabeDepartment of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.ORCID https://orcid.org/0000-0002-5334-7687

Funding

Japan Agency for Medical Research and DevelopmentJapan Association for Diabetes Education and CareJapan Society for the Promotion of ScienceSuzuken Memorial Foundation
6 · The paper itself

Abstract

AIMS/

introductionCarbohydrate responsive element-binding protein (ChREBP) is a glucose-activated transcription factor implicated in metabolic regulation and β-cell proliferation. Although in vitro studies have suggested that ChREBP promotes glucose-stimulated β-cell proliferation, its in vivo role under physiological and pathophysiological conditions remains unclear. MATERIALS AND

methodsWe generated β-cell-specific ChREBP knockout (βChrebp cKO) mice and examined β-cell proliferation and glucose metabolism under three conditions known to induce β-cell expansion: pharmacologically induced insulin resistance using the insulin receptor antagonist S961, high-fat diet (HFD) feeding, and pregnancy. β-cell proliferation was assessed by 5-Bromo-2'-deoxyuridine incorporation; islet gene expression was evaluated by quantitative PCR and RNA sequencing.

resultsβChrebp cKO mice displayed significantly impaired β-cell proliferation under both S961 treatment and HFD feeding, accompanied by decreased expression of the ChREBP target gene Rgs16. These mice also exhibited a mild defect in early-phase insulin secretion at 1 year of age and developed age-associated glucose intolerance. In contrast, pregnancy-induced β-cell proliferation and the expression of mitogenic genes (e.g., Tph2, Ccnb1, Ccnb2) were preserved in βChrebp cKO mice, and Rgs16 expression was unaffected. These findings suggest that ChREBP is critical for β-cell adaptation under hyperglycemia and insulin-resistant states, but not during normoglycemic pregnancy.

conclusionsChREBP plays a context-dependent role in regulating β-cell proliferation, particularly under metabolic stress. The ChREBP-RGS16 axis may mediate adaptive β-cell proliferation in diabetes-related conditions, and this axis represents a potential therapeutic target to preserve or restore β-cell mass in type 2 diabetes.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCell ProliferationInsulin-Secreting CellsStress, PhysiologicalTranscription FactorsAnimalsDiet, High-FatFemaleGlucoseGlucose IntoleranceInsulin ResistanceMiceMice, KnockoutPregnancyBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsGlucoseMlxipl protein, mouseTranscription FactorsChREBPRGS16β‐cell proliferation

Identifiers

PMID41983435
PMCPMC13238567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.